000285455 001__ 285455
000285455 005__ 20260305170318.0
000285455 0247_ $$2doi$$a10.1186/s13195-026-01973-1
000285455 0247_ $$2pmid$$apmid:41673920
000285455 0247_ $$2pmc$$apmc:PMC12930813
000285455 037__ $$aDZNE-2026-00237
000285455 041__ $$aEnglish
000285455 082__ $$a610
000285455 1001_ $$0P:(DE-2719)9001560$$aOeckl, Patrick$$b0$$eFirst author
000285455 245__ $$aLongitudinal changes of blood β-synuclein in cognitively unimpaired, mild cognitive impairment and sporadic Alzheimer´s disease.
000285455 260__ $$aLondon$$bBioMed Central$$c2026
000285455 3367_ $$2DRIVER$$aarticle
000285455 3367_ $$2DataCite$$aOutput Types/Journal article
000285455 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1772726512_2499
000285455 3367_ $$2BibTeX$$aARTICLE
000285455 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285455 3367_ $$00$$2EndNote$$aJournal Article
000285455 520__ $$aβ-Synuclein is an emerging synaptic blood biomarker for Alzheimer´s disease (AD) and correlates with cognitive impairment, brain atrophy and amyloid/tau pathology. Longitudinal data from individual patients are missing so far but are important to evaluate how changes of β-synuclein might be used in early diagnosis, prediction, disease progression and treatment monitoring.In this observational study, we investigated serum β-synuclein by immunoprecipitation-mass spectrometry (IP-MS) in 463 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) including clinically diagnosed cognitively unimpaired, mild cognitive impairment (MCI) and AD dementia subjects with ≥ 1 follow-up samples for 235 individuals and clinical follow-up for up to 19 years. CSF AD biomarker levels were available for 194 participants.Participants (40.0% female, n = 185) had a mean (± SD) age of 76.2 ± 6.7 years. The cross-sectional group comparison yielded higher β-synuclein levels in MCI and AD dementia compared with CU and in AD dementia vs MCI patients. Mean follow-up time of longitudinal serum samples was 2.3 ± 1.2 years. The longitudinal data indicate that β-synuclein levels are dynamic during all stages of the AD continuum (CU, MCI, dementia) with substantial inter-individual variation. β-Synuclein predicted MCI-to-dementia conversion and future cognitive decline and it performed better in discrimination of AD dementia patients than CSF neurogranin.Our longitudinal data support the use of serum β-synuclein levels for prediction of future cognitive decline and MCI-to-dementia conversion but needing confirmation. Further studies with biologically and clinically defined participants must verify the trajectories of β-synuclein during the AD continuum.The online version contains supplementary material available at 10.1186/s13195-026-01973-1.
000285455 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285455 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285455 650_7 $$2Other$$aBlood biomarker
000285455 650_7 $$2Other$$aLongitudinal observation
000285455 650_7 $$2Other$$aMild cognitive impairment
000285455 650_7 $$2Other$$aSporadic Alzheimer´s disease
000285455 650_7 $$2Other$$aSynaptic degeneration
000285455 650_7 $$2Other$$aβ-synuclein
000285455 7001_ $$00000-0003-0631-8506$$aAbu-Rumeileh, Samir$$b1
000285455 7001_ $$aWeise, Christopher M$$b2
000285455 7001_ $$00000-0003-4273-4267$$aOtto, Markus$$b3
000285455 7001_ $$aInitiative, Alzheimer’s Disease Neuroimaging$$b4$$eCollaboration Author
000285455 773__ $$0PERI:(DE-600)2506521-X$$a10.1186/s13195-026-01973-1$$gVol. 18, no. 1, p. 45$$n1$$p45$$tAlzheimer's research & therapy$$v18$$x1758-9193$$y2026
000285455 8564_ $$uhttps://pub.dzne.de/record/285455/files/DZNE-2026-00237.pdf$$yRestricted
000285455 8564_ $$uhttps://pub.dzne.de/record/285455/files/DZNE-2026-00237.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285455 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001560$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000285455 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285455 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS RES THER : 2022$$d2025-11-06
000285455 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-06
000285455 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-06
000285455 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2025-11-06
000285455 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2025-08-21T13:53:36Z
000285455 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2025-08-21T13:53:36Z
000285455 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2025-08-21T13:53:36Z
000285455 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-11-06
000285455 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-11-06
000285455 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-06
000285455 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-06
000285455 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-06
000285455 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-06
000285455 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-06
000285455 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bALZHEIMERS RES THER : 2022$$d2025-11-06
000285455 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-11-06
000285455 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-11-06
000285455 9201_ $$0I:(DE-2719)5000073$$kAG Öckl$$lTranslational Mass Spectrometry and Biomarker Research$$x0
000285455 980__ $$ajournal
000285455 980__ $$aEDITORS
000285455 980__ $$aVDBINPRINT
000285455 980__ $$aI:(DE-2719)5000073
000285455 980__ $$aUNRESTRICTED